At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 150 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 0.625 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
The University of Texas Health Science Center, Houston·interventional·Posted Feb 25, 2008·Updated Jun 6, 2017
In Brief
A Phase 2 clinical trial evaluating Bevacizumab and Conventional Laser for ROP for Retinopathy of Prematurity. Targeting 150 participants across 15 sites.
Detailed Summary
The purpose of this study was to determine the efficacy and additional advantages of intravitreal bevacizumab in the treatment of ROP for both Zone I and Zone II Posterior.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinopathy of Prematurity
CountriesUnited States
Collaborators--
Timeline
Phase 2UnknownOverdue
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartMar 2008
Primary CompletionAug 2010
Study CompletionAug 2020
TodayJul 2026
First PostedFeb 25, 2008
Enrollment StartMar 1, 2008
Primary CompletionAug 1, 2010
Study CompletionAug 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 18.4 years ago
Interventions
Bevacizumabdrug
Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
Conventional Laser for ROPprocedure
Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)